Proposed Changes to Medicare Part D Chronic Drug Costs

Where This Stands

Introduced

Committee

Floor Vote

Passed

Signed

Currently IN_COMMITTEE. The next step in the legislative lifecycle is Floor Vote.

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

If enacted, this bill would change how much Medicare beneficiaries pay for specific chronic medications by tying their to the —the price after manufacturer rebates—potentially reducing costs for seniors who rely on these drugs.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Medicare Part D enrollees

Their out-of-pocket costs for specific chronic care drugs will be calculated based on net prices rather than list prices.

Pharmacy Benefit Managers

They must account for manufacturer price concessions when determining the net price used for patient cost-sharing.

What changed

Current stage: IN_COMMITTEE.

What's next

Floor Vote.

Background

Medicare Part D is the federal program that provides prescription drug coverage to Medicare beneficiaries. context
Pharmacy Benefit Managers (PBMs) are third-party administrators that manage prescription drug benefits for health plans. context

Summary

This bill would require plans to base patient cost-sharing for certain chronic care medications on the drug's '' rather than its list price, starting in 2025. This change aims to lower out-of-pocket expenses for seniors taking medications for conditions like cardiovascular disease, respiratory issues, and blood glucose regulation.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

Which drugs are considered 'chronic care drugs' under this bill?

The bill covers specific categories including blood glucose regulators (excluding insulin), inhaled corticosteroids, bronchodilators, respiratory tract agents, anticoagulants, and cardiovascular agents.

Does this change apply to all Medicare plans?

It applies to plans, though there is an exception for plans that use flat copayments not tied to drug prices or wholesale costs.

When would these changes take effect?

The provisions are set to apply to plan years beginning on or after January 1, 2025.

Why It Matters

If enacted, this bill would change how much Medicare beneficiaries pay for specific chronic medications by tying their to the —the price after manufacturer rebates—potentially reducing costs for seniors who rely on these drugs.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift100% confidence

Shift to Net Price Calculation

The bill represents a shift toward using 'net price' as the basis for patient cost-sharing, which is a departure from traditional list-price-based models.

Medicare Part D

Connected Entities

personMr. Carter of Georgia“Co-sponsor of the bill.”Map →

personMs. Ross“Co-sponsor of the bill.”Map →

organizationEnergy and Commerce Committee“Committee responsible for considering the bill.”Map →

personMr. Peters“Co-sponsor of the bill.”Map →

personMrs. Miller-Meeks“Introduced the bill in the House of Representatives.”Map →

organizationWays and Means Committee“Committee responsible for considering the bill.”Map →

organizationU.S. Government Publishing Office“Published the Congressional Bills document.”Map →

personSecretary of Health and Human Services“Responsible for implementing the bill's regulations.”Map →

Analysis Score

0–100

Significance65
How much this matters to a regular citizen
Controversy30
Intensity of disagreement among stakeholders
Entertainment5
Compellingness for a non-policy-wonk reader
Buzz20
Current news / social attention level